Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?
Cancer Metastasis Rev
; 34(1): 129-44, 2015 Mar.
Article
en En
| MEDLINE
| ID: mdl-25726003
ABSTRACT
Approximately 1.6 million new cases of lung cancer are diagnosed annually (Jemal et al. CA A Cancer Journal for Clinicians, 61, 69-90, 2011) and it remains the leading cause of cancer-related mortality worldwide. Despite decades of bench and clinical research to attempt to improve outcome for locally advanced, good performance status patients, the 5-year survival remains less than 15 % (Molina et al. 2008). Immune checkpoint inhibitor (ICH) therapies have shown a significant promise in preclinical and clinical trails to date in the treatment of non-small cell lung cancer (NSCLC). The idea of combining these systemic immune therapies with local ablative techniques is one that is gaining momentum. Electrochemotherapy (ECT) is a unique atraumatic local therapy that has had very promising objective response rates and a number of advantages including but not limited to its immunostimulatory effects. ECT in combination with ICHs offers a novel approach for dealing with this difficult disease process.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Carcinoma de Pulmón de Células no Pequeñas
/
Electroquimioterapia
/
Inmunoterapia
/
Neoplasias Pulmonares
Límite:
Humans
Idioma:
En
Revista:
Cancer Metastasis Rev
Asunto de la revista:
NEOPLASIAS
Año:
2015
Tipo del documento:
Article